calciumdepend
protein
kinas
cdpk
promis
target
develop
antiapicomplexan
drug
hui
et
al
kugelstadt
et
al
ojo
et
al
apicomplexan
cdpk
belong
superfamili
serinethreonin
kinas
among
abund
class
calcium
sensor
crucial
multipl
physiolog
function
glide
cell
invas
egress
replic
kugelstadt
et
al
ojo
et
al
importantli
cdpk
absent
mammalian
host
render
excel
parasitespecif
drug
target
billker
et
al
larson
et
al
ojo
et
al
cdpk
apicomplexan
parasit
effect
target
bump
kinas
inhibitor
bki
class
synthet
competit
inhibitor
atpbind
bki
select
base
small
gatekeep
residu
present
apicomplexan
keyloun
et
al
allow
bki
larg
aromat
moieti
display
posit
pyrazolopyrimidin
scaffold
select
target
apicomplexan
enzym
mammalian
parasit
kinas
wide
rang
bki
alreadi
evalu
efficaci
coccidian
parasit
toxoplasma
gondii
doggett
et
al
johnson
et
al
winzer
et
al
neospora
caninum
ojo
et
al
et
al
besnoitia
besnoiti
et
al
sarcocysti
neurona
ojo
et
al
cryptosporidium
parvum
hulverson
et
al
schaefer
et
al
consist
side
effect
bki
observ
vivo
trial
cystoisospora
sui
close
rel
gondii
n
caninum
within
famili
sarcocystida
ogedengb
et
al
samarasingh
et
al
therefor
exist
ortholog
c
sui
consequ
efficaci
bki
origin
develop
inhibit
expect
c
sui
syn
isospora
sui
one
lead
caus
diarrheal
diseas
suckl
piglet
diseas
usual
nonfat
high
morbid
affect
litter
lindsay
et
al
roepstorff
et
al
sayd
kawazo
cystoisosporosi
character
waterytopasti
nonhemorrhag
diarrhea
impair
weight
gain
reduc
uneven
wean
weight
piglet
consequ
impos
signific
econom
loss
pig
farm
industri
mundt
et
al
shrestha
et
al
triazinon
toltrazuril
commerci
market
compound
avail
effect
treatment
cystoisosporosi
due
enforc
strict
regul
use
anticoccidi
mani
countri
importantli
emerg
resist
toltrazuril
c
sui
shrestha
et
al
search
altern
effect
therapeut
control
strategi
cystoisosporosi
prioriti
bki
target
apicomplexan
shown
inhibit
parasit
infect
vitro
andor
repres
anim
model
present
studi
bki
success
amelior
cystoisosporosi
natur
host
pig
employ
experiment
infect
two
differ
strain
c
sui
vari
suscept
toltrazuril
vivo
result
support
vitro
demonstr
efficaci
c
sui
merozoit
cell
cultur
genet
function
studi
put
target
enzym
repeat
oral
applic
bki
show
mark
system
exposur
treatment
significantli
reduc
oocyst
excret
diarrhea
improv
bodi
weight
gain
treat
piglet
result
anim
experiment
vitro
studi
thu
valid
bki
potenti
therapeut
candid
porcin
cystoisosporosi
also
possibl
implic
efficaci
studi
bki
cystosiospororsi
mammalian
host
bki
metabolit
synthes
puriti
assess
high
perform
liquid
chromatographi
hplc
previous
describ
johnson
et
al
vidadala
et
al
bki
anim
studi
synthes
va
bio
cherlap
hyderabad
india
puriti
hplc
nuclear
magnet
reson
nmr
singl
impur
hplc
less
part
per
million
heavi
metal
contamin
bki
metabolit
hulverson
et
al
lee
et
al
synthes
follow
bki
ad
concentr
hydrochlor
acid
stir
h
reaction
mixtur
first
neutral
basifi
ph
use
aqueou
sodium
bicarbon
follow
extract
ethyl
acet
ml
organ
layer
combin
concentr
rotari
evapor
purifi
revers
phasehplc
acetonitril
water
yield
bki
metabolit
synthesi
bki
nmr
mhz
j
hz
j
hz
j
hz
j
hz
j
hz
ms
esi
mz
mh
requir
hplc
puriti
amino
acid
sequenc
relev
bkibind
protein
close
relat
apicomplexan
speci
gondii
access
n
caninum
neurona
b
besnoiti
hammondia
hammondi
obtain
toxodb
http
toxodborg
ncbi
http
wwwncbinlmnihgov
compar
amino
acid
sequenc
protein
kinas
predict
c
sui
genom
access
number
use
blastp
http
blastncbinlmnihgovblastcgi
identifi
c
sui
ortholog
sequenc
align
analyz
use
clustal
omega
siever
et
al
complet
read
frame
amplifi
pcr
clone
ligat
independ
clone
lic
site
protein
express
vector
ojo
et
al
express
vector
plasmid
dna
purifi
use
zymopur
plasmid
kit
zymo
research
irvin
ca
compar
analysi
nucleotid
sequenc
dna
insert
entri
use
confirm
put
gene
recombin
express
perform
rosetta
oxford
escherichia
coli
invitrogen
carlsbad
ca
usa
use
studier
autoinduct
protocol
studier
solubl
recombin
enzym
purifi
describ
previous
ojo
et
al
recombin
enzym
activ
inhibit
kinas
phosphoryl
properti
small
molecul
inhibitor
measur
nonradioact
promega
madison
wi
usa
luciferas
assay
readout
envis
multilabel
plate
reader
perkinelm
waltham
base
chang
atp
concentr
presenc
peptid
substrat
plktide
signalchem
richmond
bc
canada
peptid
sequenc
ckklgedqaeeisddlledslsded
use
receptor
phosphat
group
donat
atp
catalyz
phosphoryl
reaction
activ
assay
reaction
buffer
contain
mm
acid
hepe
ph
bovin
serum
albumin
bsa
wv
mm
mm
ethylen
glycolbi
ether
n
n
ntetraacet
acid
egta
without
mm
reaction
mixtur
includ
nm
plktide
plate
dilut
reaction
initi
addit
atp
incub
min
rpm
final
concentr
compound
result
reduct
enzym
activ
determin
thermal
stabil
recombin
presenc
absenc
inhibitor
determin
format
previous
describ
crowther
et
al
ojo
et
al
final
assay
volum
contain
reaction
mixtur
enzym
inhibitor
sypro
orang
dye
invitrogen
carlsbad
ca
dimethyl
sulfoxid
dmso
presenc
absenc
calcium
reaction
perform
buffer
solut
contain
mm
hepe
ph
mm
nacl
glycerol
mm
dithiothreitol
sodium
azid
without
egta
calcium
ion
chelat
intern
control
compris
dmso
includ
assay
plate
addit
control
use
previous
character
recombin
enzym
also
includ
assay
perform
realtim
pcr
system
appli
biosystem
assay
perform
independ
least
two
time
ojo
et
al
intestin
porcin
epitheli
dsmz
acc
wwwdsmzde
maintain
cultur
medium
supplement
fetal
calf
serum
penicillinstreptomycin
gibco
via
thermofish
vienna
austria
describ
earlier
worliczek
et
al
bki
store
mm
stock
solut
dmso
cell
viabil
presenc
dmso
bki
determin
colorimetr
cell
prolifer
assay
roch
diagnost
gmbh
mannheim
germani
accord
manufactur
protocol
cell
plate
cellswel
incub
one
day
seed
differ
concentr
bki
nm
nm
nm
nm
nm
dilut
cultur
medium
dmso
quadrupl
grown
day
humidifi
incub
cultiv
reagent
ad
well
incub
h
absorb
measur
nm
refer
wavelength
nm
use
elisa
plate
reader
filtermax
molecular
devic
sunnyval
ca
usa
cell
viabil
compar
dmsoonli
mediumonli
control
confluent
cell
cellswel
grown
well
plate
infect
excyst
sporozoit
c
sui
wieni
describ
earlier
worliczek
et
al
one
day
cell
seed
ratio
infect
cell
incub
presenc
bki
nm
cultur
medium
continu
day
day
post
infect
dpi
calcul
inhibitori
concentr
treatment
day
dpi
medium
contain
bki
replac
normal
cultur
medium
cultur
maintain
dpi
evalu
growth
parasit
supernat
collect
free
merozoit
count
pool
sampl
dpi
quadrupl
well
cchip
dispos
hemocytomet
nanoentekroth
lactan
graz
austria
assay
includ
mediumonli
dmsoonli
control
quadrupl
confluent
cell
cellswel
grown
cultur
plate
vwr
vienna
austria
infect
c
sui
sporozoit
next
day
cell
incub
predetermin
nm
nm
concentr
bki
see
section
efficaci
test
five
day
infect
cell
incub
dmso
serv
control
h
h
h
h
incub
medium
supernat
remov
monolay
wash
twice
phosphat
buffer
salin
pb
fix
glutaraldehyd
merck
darmstadt
germani
sodium
phosphat
buffer
ph
min
cell
care
collect
use
rubber
scraper
tpp
switzerland
subject
centrifug
room
temperatur
min
supernat
remov
cell
postfix
osmium
tetroxid
merck
h
dehydr
alcohol
seri
propylen
oxid
merck
cell
embed
glycidyl
ether
serva
heidelberg
germani
ultrathin
section
cut
leica
ultramicrotom
leica
ultracut
vienna
austria
stain
uranyl
acet
sigmaaldrich
vienna
austria
lead
citrat
examin
zeiss
tem
electron
microscop
carl
zeiss
oberkochen
germani
oper
kv
total
convent
rais
piglet
four
crossbr
sow
landrac
x
larg
white
randomli
alloc
four
treatment
group
tabl
pregnant
sow
move
anim
husbandri
facil
institut
parasitolog
univers
veterinari
medicin
vienna
austria
two
week
farrow
acclimat
hous
condit
sow
hous
straw
individu
farrow
crate
fed
daili
commerci
feed
free
coccidiostat
piglet
receiv
milk
sow
follow
starter
feed
second
week
life
fresh
drink
water
provid
ad
libitum
sow
piglet
clinic
healthi
piglet
bodi
weight
g
studi
day
sd
includ
studi
first
day
birth
piglet
consid
sd
clinic
studi
last
day
sd
follow
blind
random
experiment
block
design
individu
piglet
experiment
unit
procedur
involv
anim
approv
anim
ethic
committe
univers
veterinari
medicin
vienna
nation
author
accord
anim
experi
act
tierversuchsgesetz
licens
number
austrian
feder
ministri
scienc
health
economi
toltrazurilsensit
laboratori
strain
c
sui
wieni
joachim
mundt
toltrazurilresist
field
isol
c
sui
hollandi
shrestha
et
al
maintain
passag
regularli
suckl
piglet
everi
month
product
infecti
oocyst
institut
parasitolog
univers
veterinari
medicin
vienna
austria
avoid
unintend
mix
two
strain
procedur
strain
mainten
experiment
infect
carri
separ
trial
complet
clean
disinfect
farrow
unit
trial
oocyst
c
sui
isol
fecal
sampl
purifi
describ
earlier
worliczek
et
al
sporul
purifi
oocyst
aqueou
potassium
dichrom
solut
pour
petri
dish
aerat
twice
daili
incub
room
temperatur
day
sporul
oocyst
store
aqueou
potassium
dichrom
solut
use
piglet
oral
infect
sd
experiment
setup
see
tabl
singl
dose
approxim
sporul
oocyst
respect
c
sui
strain
use
flexibl
plastic
pasteur
pipett
immedi
infect
piglet
either
treat
bki
mock
treat
solvent
tween
ethanol
nacl
twice
daili
five
day
sd
sd
fine
powder
bki
dissolv
solvent
yield
bki
solut
use
treat
individu
piglet
group
wienbki
hollbki
twice
daili
rate
mgkg
bodi
weight
bw
ml
bki
bw
furthermor
piglet
infect
hollandi
isol
c
sui
hollbki
hollctrl
addit
treat
mgkg
bw
toltrazuril
bayer
anim
health
monheim
germani
assur
toltrazurilresist
parasit
present
posttreat
observ
conduct
veterinarian
immedi
end
treatment
h
posttreat
account
advers
event
associ
treatment
piglet
examin
posttreat
system
region
respons
abnorm
behavior
salivationvomit
ocular
discharg
abnorm
locomot
etc
addit
piglet
observ
daili
cours
studi
ensur
good
gener
health
condit
requir
veterinari
care
record
address
efficaci
bki
evalu
assess
oocyst
excret
fecal
consist
bodi
weight
develop
individu
fecal
sampl
collect
daili
sd
sd
evalu
fecal
consist
oocyst
excret
fecal
consist
score
immedi
sampl
fecal
score
fs
normalfirm
fs
pasti
fs
semiliquid
fs
liquid
fs
fs
consid
diarrhea
fecal
sampl
screen
presenc
oocyst
qualit
autofluoresc
af
follow
quantit
modifi
mcmaster
techniqu
joachim
et
al
furthermor
pool
fecal
sampl
litter
sd
examin
presenc
enteropathogen
rotaviru
coronaviru
escherichia
coli
clostridium
perfringen
bodi
weight
piglet
record
sd
addit
day
treatment
calcul
treatment
dose
three
piglet
group
wienbki
two
piglet
group
wienctrl
sacrif
sd
confirm
onset
oocyst
excret
mock
treat
group
collect
jejun
tissu
section
histopatholog
transmiss
electron
microscopi
tem
addit
jejun
mucos
scrape
collect
sacrif
piglet
end
experi
sd
remain
piglet
group
wienbki
wienctrl
hollbki
hollctrl
sacrif
blood
sampl
edta
collect
piglet
group
wienbki
first
treatment
h
first
treatment
treatment
h
treatment
end
studi
sd
plasma
sampl
obtain
centrifug
min
store
use
remain
piglet
group
wienbki
n
sacrif
end
studi
urin
sampl
collect
determin
compound
exposur
bki
metabolit
bki
metabolit
bki
metabolit
fig
hulverson
et
al
lee
et
al
extract
plasma
urin
sampl
use
formic
acid
intern
standard
standard
curv
prepar
comparison
quantif
sampl
analyz
lcmsm
analysi
acquiti
ultra
perform
liquid
chromatographi
uplc
system
tandem
water
xevo
tq
micro
water
corpor
milford
usa
necropsi
jejun
mucos
scrape
tissu
section
collect
sacrif
piglet
sd
jejun
section
histopatholog
fix
neutral
buffer
formalin
embed
wax
process
section
stain
hematoxylin
eosin
h
e
institut
patholog
forens
veterinari
medicin
univers
veterinari
medicin
vienna
austria
airdri
mucos
scrape
jejunum
fix
methanol
stain
giemsa
use
standard
procedur
h
e
tissu
section
giemsa
stain
mucos
smear
examin
presenc
development
stage
c
sui
magnif
statist
calcul
vivo
trial
perform
rstudio
version
rstudio
team
descript
statist
microsoft
excel
microsoft
inc
vienna
austria
graphpad
prism
version
window
graphpad
softwar
san
diego
california
usa
differ
clinic
parasitolog
paramet
group
analyz
anova
case
normal
distribut
varianc
homogen
data
kruskalw
rank
sum
test
case
event
signific
omnibu
test
parametr
nonparametr
posthoc
test
multipl
comparison
perform
accord
tukey
conov
respect
pvalu
adjust
bonferroni
vitro
assay
evalu
ttest
graphpad
prism
version
window
signific
report
p
test
efficaci
bki
vitro
percentag
inhibit
calcul
follow
inhibit
compar
sequenc
analysi
bkibind
cdpk
gondii
n
caninum
neurona
h
hammondi
b
besnoiti
predict
protein
kinas
c
sui
identifi
put
ortholog
fig
kinas
c
sui
show
high
degre
sequenc
similar
atp
bind
domain
amino
acid
ident
mention
apicomplexan
parasit
includ
glycin
gatekeep
residu
express
e
coli
analysi
recombin
express
sdspage
show
protein
band
match
predict
molecular
weight
kda
uncleav
histag
supplementari
fig
recombin
character
thermal
stabil
assay
substanti
shift
melt
temperatur
observ
presenc
bki
presenc
egta
rel
metabolit
presenc
egta
compound
dmso
control
supplementari
fig
recombin
found
protein
kinas
activ
transfer
phosphat
group
atp
plktide
concentr
bki
requir
inhibit
enzym
activ
lower
nanomolar
rang
bki
nm
bki
metabolit
use
neg
control
valu
nm
vitro
assay
establish
assess
viabil
cell
upon
exposur
bki
incub
uninfect
cell
bki
concentr
caus
signific
chang
cell
prolifer
viabil
supplementari
fig
compar
mediumonli
dmsoonli
control
p
moreov
alter
morpholog
cell
detect
upon
inspect
light
microscopi
incub
cell
bki
day
significantli
reduc
absorb
directli
proport
cell
viabil
compar
mediumonli
p
dmsoonli
p
control
consequ
highest
concentr
bki
use
subsequ
cultur
assay
nm
bki
inhibit
prolifer
c
sui
merozoit
cultur
cell
nm
parasit
prolifer
almost
complet
inhibit
nm
incub
host
cell
immedi
infect
dpi
result
signific
dosedepend
reduct
free
merozoit
count
dpi
test
concentr
bki
higher
nm
p
fig
effect
continu
bki
treatment
concentr
c
sui
propag
cell
visual
light
microscopi
bki
treat
cultur
mark
reduct
number
intracellular
free
merozoit
observ
fig
intracellular
free
merogon
stage
frequent
observ
dmsoonli
control
cultur
light
microscop
compar
treat
cultur
howev
concentr
appar
effect
ultrastructur
c
sui
merozoit
analyz
tem
fig
although
fewer
intracellular
merozoit
observ
longitudin
section
treat
cultur
confin
within
parasitophor
vacuol
surround
parasitophoru
vacuol
membran
exhibit
typic
featur
apicomplexan
includ
apic
complex
spiral
arrang
conoid
micronem
rhoptri
dens
granul
fig
treatment
bki
complet
suppress
oocyst
excret
group
wienbki
significantli
limit
excret
group
hollbki
singl
posit
sampl
sd
fig
contrast
oocyst
shed
observ
mock
treat
control
group
wienctrl
hollctrl
earli
sd
sd
piglet
group
excret
oocyst
least
mean
durat
oocyst
excret
day
group
wienctrl
day
group
hollctrl
supplementari
tabl
paramet
relat
oocyst
excret
number
day
mcmaster
detect
oocyst
excret
mean
number
oocyst
per
gram
fece
opg
area
curv
auc
opg
significantli
differ
treat
control
group
irrespect
c
sui
strain
use
tabl
none
piglet
diarrhea
day
infect
mean
daili
fs
group
wienbki
exceed
throughout
studi
significantli
lower
wienctrl
fig
tabl
three
sampl
group
hollbki
fs
fs
group
hollbki
significantli
lower
hollctrl
group
throughout
studi
tabl
maximum
preval
diarrhea
group
hollctrl
averag
durat
day
group
wienctrl
averag
durat
day
wateri
diarrhea
fs
observ
piglet
group
wienctrl
hollctrl
averag
day
respect
bodi
weight
significantli
differ
group
sd
day
random
p
daili
weight
gain
total
weight
gain
sd
sd
significantli
higher
group
wienbki
compar
wienctrl
wherea
differ
found
treat
control
piglet
infect
c
sui
hollandi
tabl
acut
phase
infect
sd
mean
bodi
weight
significantli
higher
bkitreat
piglet
compar
control
group
irrespect
c
sui
strain
use
fig
also
signific
neg
correl
mean
fecal
score
total
weight
gain
observ
piglet
p
fecal
sampl
pool
litter
sd
neg
rotaviru
coronaviru
wherea
e
coli
cl
perfringen
could
detect
litter
piglet
show
treatmentrel
advers
effect
requir
veterinari
intervent
throughout
studi
period
neither
visibl
sign
toxic
clinic
relev
system
regionalloc
respons
relat
treatment
observ
treat
group
h
e
stain
section
midjejunum
examin
histopatholog
chang
characterist
c
sui
infect
presenc
development
stage
parasit
compar
normal
jejun
villi
bkitreat
piglet
mock
treat
control
piglet
exhibit
stunt
villi
atrophi
fusion
fig
c
numer
infect
epitheli
cell
distinct
cluster
merozoit
c
sui
observ
stain
jejun
section
mock
treat
control
piglet
fig
giemsastain
mucos
scrape
smear
mock
treat
piglet
reveal
presenc
matur
crescentshap
merozoit
within
parasitophor
vacuol
fig
neither
histopatholog
alter
morpholog
villi
presenc
endogen
stage
c
sui
could
detect
tissu
section
mucos
scrape
smear
bkitreat
piglet
bki
metabolit
bki
metabolit
bki
metabolit
hulverson
et
al
lee
et
al
measur
plasma
urin
sampl
tabl
bki
concentr
observ
h
dose
rose
h
dose
without
increas
h
dose
metabolit
level
remain
low
measur
time
point
compound
detect
plasma
urin
dpi
role
cdpk
potenti
molecular
target
chemotherapeut
intervent
apicomplexan
parasit
previous
studi
parasit
differ
taxonom
group
apicomplexan
regul
calciumdepend
pathway
micronem
secret
facilit
glide
locomot
govern
host
cell
attach
invas
egress
billker
et
al
carruth
sibley
kieschnick
et
al
wei
et
al
contrari
mammalian
kinas
presenc
glycin
gatekeep
residu
atpbind
site
apicomplexan
enabl
bki
fit
perfectli
small
hydrophob
pocket
render
highli
select
promis
compound
therapeut
intervent
parasit
identifi
kinas
c
sui
show
high
degre
sequenc
similar
atp
bind
domain
amino
acid
ident
glycin
gatekeep
residu
unlik
previous
studi
apicomplexan
recombin
cdpk
enzym
peptid
substrat
plartlsvaglpgkk
compat
measur
kinas
activ
vitro
inspit
highli
conserv
amino
acid
sequenc
similar
enzym
activ
site
howev
autophosphoryl
activ
could
measur
presenc
absenc
calcium
without
suitabl
peptid
substrat
experiment
analysi
confirm
calcium
depend
determin
phosphoryl
reaction
use
egta
chelat
presenc
absenc
plktide
signalchem
richmond
bc
canada
peptid
substrat
ckklgedqaeeisddlledslsded
calcium
depend
regul
enzym
activ
verif
belong
famili
previous
describ
apicomplexan
cdpk
van
voorhi
et
al
futur
studi
need
determin
potenti
diverg
function
natur
substrat
pathway
rel
cdpk
nonetheless
sensit
bki
direct
inhibit
enzym
activ
confirm
direct
enzym
activ
assay
demonstr
indirectli
thermal
stabil
assay
increas
thermal
melt
temperatur
recombin
presenc
bki
indic
bind
either
ligand
base
previou
studi
show
correl
bind
affin
predict
thermal
shift
direct
measur
enzym
inhibit
compound
ojo
et
al
addit
concentr
bki
measur
recombin
nm
corrobor
efficaci
compound
vitro
doserespons
assay
nm
valid
related
shown
improv
egta
thermal
stabil
enzym
rel
control
presum
bound
recombin
enzym
supplementari
fig
previous
report
scheel
et
al
result
seem
counterintuit
sinc
calcium
activ
enzym
yet
chelat
appear
maxim
thermal
stabil
scheel
et
al
vitro
valu
obtain
bki
nanomolar
rang
support
data
publish
efficaci
c
parvum
hulverson
et
al
c
homini
lee
et
al
treatment
c
sui
infect
cell
concentr
bki
five
day
significantli
reduc
number
free
merozoit
seen
light
microscopi
tem
without
appar
effect
ultrastructur
c
sui
merozoit
toxoplasma
neospora
treat
bki
bki
morpholog
alter
vitro
seen
follow
longer
treatment
durat
high
dose
ojo
et
al
winzer
et
al
howev
would
option
vitro
model
employ
sinc
host
cell
sensit
higher
concentr
bki
significantli
c
sui
timelimit
development
phase
termin
oocyst
product
compar
perman
lytic
cycl
tachyzoit
replic
vitro
toxoplasma
neospora
bki
shown
inhibit
host
cell
invas
egress
cytokinesi
vitro
well
reduc
cerebr
parasit
burden
standard
murin
model
cystform
apicomplexan
parasit
gondii
n
caninum
doggett
et
al
ojo
et
al
winzer
et
al
calf
clinic
model
acut
porcin
model
cryptosporidiosi
treatment
mgkg
bw
bki
twice
daili
five
day
significantli
reduc
clinic
diarrhea
fecal
oocyst
excret
improv
overal
health
infect
anim
lee
et
al
schaefer
et
al
treatment
regim
adopt
present
vivo
studi
evalu
therapeut
efficaci
bki
candid
bki
fewer
known
side
effect
compar
test
bki
hulverson
et
al
porcin
cystoisosporosi
natur
host
experiment
model
suckl
piglet
cystoisosporosi
previous
employ
evalu
efficaci
anticoccidi
treatment
base
quantit
qualit
oocyst
shed
fecal
consistencydiarrhea
bodi
weight
develop
gener
anim
health
joachim
mundt
joachim
et
al
mundt
et
al
shrestha
et
al
mammalian
speci
anticoccidi
consid
effici
vivo
oocyst
shed
notic
reduc
indic
reduc
environment
contamin
parasit
stage
ie
reduc
infect
pressur
anim
health
weight
gain
improv
compar
mocktreat
control
joachim
et
al
treatment
bki
significantli
reduc
oocyst
excret
diarrhea
piglet
infect
c
sui
presenc
enteropathogen
high
efficaci
bki
reduc
oocyst
excret
diarrhea
compar
toltrazuril
mundt
et
al
joachim
mundt
joachim
et
al
observ
irrespect
parasit
strain
employ
indic
bki
therapi
could
effect
combat
toltrazuril
suscept
well
resist
c
sui
suggest
lesion
induc
intracellular
replic
c
sui
impair
physiolog
function
balanc
intestin
therefor
neg
impact
bodi
weight
develop
piglet
mundt
et
al
similar
effect
c
sui
infect
observ
studi
significantli
lower
daili
bodi
weight
gain
total
weight
gain
control
piglet
compar
bki
treat
piglet
acut
phase
infect
effect
tend
wane
follow
period
sd
might
due
gradual
heal
intestin
epithelium
matur
immun
system
increas
piglet
age
gener
featur
coccidiosi
histolog
section
mock
treat
control
piglet
reveal
cuboid
villou
epithelium
shorten
villi
villou
fusion
togeth
numer
merogon
stage
c
sui
within
parasitophoru
vacuol
comparison
morpholog
alter
gut
observ
treat
piglet
underpin
hypothesi
c
suisinduc
intestin
damag
disturb
physiolog
function
intestin
ultim
lead
diarrhea
malabsorpt
nutrient
reduc
weight
gain
lindsay
et
al
stuart
et
al
bki
achiev
therapeut
concentr
piglet
plasma
micromolar
rang
far
effect
vitro
level
nm
plasma
concentr
alreadi
reach
peak
h
dose
concentr
gradual
increas
h
dose
indic
accumul
drug
plasma
treatment
twice
daili
day
consequ
assum
similar
level
found
infect
gut
epithelium
vivo
parasit
constantli
expos
high
concentr
bki
could
reason
complet
cessat
parasit
develop
replic
vivo
compar
vitro
experi
result
accord
previou
studi
bki
c
homini
infect
piglet
report
low
concentr
metabolit
dose
period
pharmacokinet
studi
piglet
determin
concentr
bki
gastrointestin
tissu
time
would
warrant
better
understand
relationship
efficaci
exposur
infect
site
also
sinc
plasma
level
reach
observ
concentr
dose
well
concentr
show
effect
vitro
cell
viabil
multidos
toxic
studi
includ
blood
chemistri
histopatholog
would
warrant
fulli
assess
effect
bki
might
host
speci
summari
present
studi
evalu
therapeut
efficaci
pharmacokinet
safeti
paramet
bki
porcin
cystoisosporosi
experiment
infect
natur
host
applic
singl
drug
concentr
one
major
limit
studi
due
possibl
determin
minim
effect
drug
concentr
develop
practic
drug
applic
scheme
oral
applic
bki
highli
effect
reduc
oocyst
shed
diarrhea
improv
bodi
weight
gain
piglet
infect
c
sui
includ
toltrazurilresist
hollandi
isol
without
advers
effect
success
outcom
vitro
cultur
anim
infect
model
porcin
cystoisosporosi
also
strongli
argu
develop
bki
chemotherapeut
compound
diseas
pig
mammal
includ
human
shrestha
et
al
howev
bki
therapi
field
might
practic
issu
owe
need
multipl
dose
therefor
futur
studi
bki
concentr
toward
eas
drug
handl
reduc
treatment
frequenc
dr
wesley
c
van
voorhi
offic
own
stock
paratheratech
inc
compani
tri
bring
bki
anim
health
market
help
design
experi
edit
paper
role
perform
interpret
result
